| Daniel J Darnold, MD | |
|
312 9th St Sw, Suite 1200, Waverly, IA 50677-2929 | |
| (319) 352-4340 | |
| (319) 352-0745 |
| Full Name | Daniel J Darnold |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 312 9th St Sw, Waverly, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851378970 | NPI | - | NPPES |
| 1851378970 | Medicaid | IA | |
| 080078031 | Other | IA | RR MEDICARE |
| 5073312 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28762 (Iowa) | Primary |
| Entity Name | Iowa Physicians Clinic Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.
The more dots there are, the more accurate a picture you get when you connect them. Cancer researchers adopting that philosophy have developed a new imaging technology that could give scientists the ability to simultaneously measure as many as 100 or more distinct features in or on a single cell. In a disease such as cancer, that capability would provide a much better picture of what is going on in individual tumor cells.
Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it will seek stockholder approval of an authorization enabling its Board of Directors in its discretion to affect a reverse stock split in the range of one-for-three to one-for-five shares of common stock in the near future, if required to maintain NASDAQ listing. The authorization will be voted upon during a special meeting of stockholders to be held on Monday, August 9th.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel J Darnold, MD 312 9th St Sw, Suite 1200, Waverly, IA 50677-2929 Ph: (319) 352-4340 | Daniel J Darnold, MD 312 9th St Sw, Suite 1200, Waverly, IA 50677-2929 Ph: (319) 352-4340 |
News Archive
Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.
The more dots there are, the more accurate a picture you get when you connect them. Cancer researchers adopting that philosophy have developed a new imaging technology that could give scientists the ability to simultaneously measure as many as 100 or more distinct features in or on a single cell. In a disease such as cancer, that capability would provide a much better picture of what is going on in individual tumor cells.
Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it will seek stockholder approval of an authorization enabling its Board of Directors in its discretion to affect a reverse stock split in the range of one-for-three to one-for-five shares of common stock in the near future, if required to maintain NASDAQ listing. The authorization will be voted upon during a special meeting of stockholders to be held on Monday, August 9th.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia.
› Verified 6 days ago
Sarah Ann Krukow, ARNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1644 Easton Ave, Waverly, IA 50677 Phone: 319-239-0500 | |
Daniel Brian Eggers, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 312 9th St Sw, Waverly, IA 50677 Phone: 319-352-4120 | |
Dr. Courtney C Bochmann, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 312 9th St Sw, Waverly, IA 50677 Phone: 319-483-1390 Fax: 319-483-1399 | |
Timothy C Horrigan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 217 20th St Nw, Waverly, IA 50677 Phone: 319-352-9500 Fax: 319-352-9509 | |
Stephanie R. Koos, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 312 9th St Sw, Suite 1200, Waverly, IA 50677 Phone: 319-352-4340 Fax: 319-352-0745 | |
Todd Larry Shover, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 312 9th St Sw, Waverly, IA 50677 Phone: 319-352-4120 | |
Cassie Mae Stone, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 217 20th St Nw, Waverly, IA 50677 Phone: 319-352-9500 |